Nissay Asset Management Corp Japan Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Nissay Asset Management Corp Japan boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,636 shares of the biopharmaceutical company's stock after purchasing an additional 1,767 shares during the period. Nissay Asset Management Corp Japan's holdings in Regeneron Pharmaceuticals were worth $19,103,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth $26,000. Western Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at about $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $29,000. Finally, Trust Co. of Vermont purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $29,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on REGN. Cantor Fitzgerald increased their price target on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an "overweight" rating in a report on Friday, July 31st. Leerink Partners lifted their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a report on Monday, August 17th. BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a report on Monday, May 18th. Royal Bank Of Canada upped their target price on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a "sector perform" rating in a research report on Friday, July 31st. Finally, Wall Street Zen upgraded Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 15th. Fifteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $800.36.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares of the company's stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director owned 1,703 shares of the company's stock, valued at approximately $1,362,400. The trade was a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock worth $1,090,030 over the last ninety days. 6.97% of the stock is owned by insiders.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $794.19 on Friday. The firm has a market cap of $81.77 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 1.35 and a beta of 0.22. The firm's 50-day simple moving average is $717.52 and its 200-day simple moving average is $718.38. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the company posted $12.81 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source